Thomas Hoffmann

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 4

Top Venues

Science (New York, N.Y.)

EMBO molecular medicine

eLife

Pharmaceutics

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Hoffmann, Alexandra Hörmann, Maja Corcokovic, Jakub Zmajkovic, Matthias Hinterndorfer, Jasko Salkanovic, Fiona Spreitzer, Anna Köferle, Katrin Gitschtaler, Alexandra Popa, Sarah Oberndorfer, Florian Andersch, Markus Schaefer, Michaela Fellner, Nicole Budano, Jan G Ruppert, Paolo Chetta, Melanie Wurm, Johannes Zuber, Ralph A Neumuller
Precision RNAi using synthetic shRNAmir target sites. eLife 12 (2023)
Michela Carlet, Karin Schmelz, Jenny Vergalli, Tobias Herold, Daniela Senft, Vindi Jurinovic, Thomas Hoffmann, Jutta Proba, Nina Weichert, Christian Junghanß, Mareike Roth, Georg Eschenburg, Malwine Jeanette Barz, Guenter Henze, Cornelia Eckert, Angelika Eggert, Johannes Zuber, Patrick Hundsdoerfer, Irmela Jeremias
X-linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL. EMBO molecular medicine (2022)
Aditya R Darade, Maria Lapteva, Thomas Hoffmann, Markus Mandler, Achim Schneeberger, Yogeshvar N Kalia
Effect of mRNA Delivery Modality and Formulation on Cutaneous mRNA Distribution and Downstream eGFP Expression. Pharmaceutics 14 (1) (2022)
Matthias Muhar, Anja Ebert, Tobias Neumann, Christian Umkehrer, Julian Jude, Corinna Wieshofer, Philipp Rescheneder, Jesse J Lipp, Veronika A Herzog, Brian Reichholf, David A Cisneros, Thomas Hoffmann, Moritz F Schlapansky, Pooja Bhat, Arndt von Haeseler, Thomas Köcher, Anna C Obenauf, Johannes Popow, Stefan L Ameres, Johannes Zuber
SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis. Science (New York, N.Y.) 360 (6390) (2018)

Thomas Hoffmann.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Thomas Hoffmann